Shogen Boku

23PUBLICATIONS

143CO-AUTHORS

Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (23)

Sort by Publication Date:

|Jul 01, 2026

Identification of a Novel <i>GOLGB1-RET</i> Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

|May 18, 2026

Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss Across Advanced Solid Tumors.

|May 04, 2026

Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer.

|Mar 30, 2026

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki

|Mar 25, 2026

Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Nodoka Umezaki, Shogen Boku, Yoshiyuki Matsuo

|Mar 15, 2026

Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.

Shogen Boku, Masato Kita, Tatsuki Ikoma

Pageof 4

Frequent Collaborators

Takayuki Yoshino

Yoshiaki Nakamura

Takao Fujisawa

Hideaki Bando

Eiji Oki

Susumu Okano

Nobuhiro Shibata

Shigenori Kadowaki

Tomohiro Nishina

Hironaga Satake

Frequent Collaborators

Takayuki Yoshino

Yoshiaki Nakamura

Takao Fujisawa

Hideaki Bando